|Thursday, July 27, 2017||
Click the diagram above
to view the XBL Navigator.
XenoBiotic Laboratories and SOLVO Biotechnology Establish Strategic Partnership to Provide In vitro Transporter Services in the United States
Plainsboro, NJ and Szeged/Budaor Hungary, April 23, 2012 - XenoBiotic Laboratories (XBL) and Solvo Biotechnology (SOLVO) today announce the formation of a strategic partnership in which in vitro transporter services will be offered at XBL’s laboratories in Plainsboro, New Jersey, United States. Under this partnership the comprehensive efflux and uptake transporter assays currently offered by SOLVO at its facility in Hungary will be transferred and established in XBL’s research facilities in Plainsboro, New Jersey. These services will be made available as a research service to the pharmaceutical industry either through SOLVO or XBL business contacts.
The role of transporters in drug development and the demand for studying drug-transporter interactions has increased dramatically over the past 2-3 years. To quote the 2012 FDA Draft Guidance, “Similar to CYP enzymes, transporters may be inhibited or induced. Inhibition of transporters by interacting drugs can lead to altered exposure of other drugs that are substrates of transporters. Therefore, the potential for an investigational drug as a substrate, inhibitor, or inducer for transporters should be evaluated during drug development” (FDA Drug Interaction Draft Guidance, February 17, 2012, p47). SOLVO (www.solvo.com) was the first to commercialize transporter assays when it entered the market in 1999, and has been a dominant player ever since. SOLVO is the top innovative transporter specialized contract research laboratory (CRO) in the market, offering consultancy services and the widest array of in vitro transporter assays including all assays needed to comply with the current FDA draft guidance and EMA guidelines, and the current market leader in Europe and the US. “We are pleased to be able to partner with SOLVO to provide a comprehensive set of high quality transporter and drug development services to our clients”, commented Dr. Jinn Wu, President and CEO of XenoBiotic Laboratories.
XBL, with global headquarters near Princeton, New Jersey, currently provides in vivo and in vitro drug metabolism studies that include CYP and phase II enzyme inhibition, induction and phenotyping assays. “Adding transporter assays will further compliment our in vitro drug interaction study capabilities, and offer our clients a comprehensive set of ADME services as part of their drug development program”, remarked Dr. Dennis Heller, Vice President of Pharmaceutical Development at XBL.
“XBL’s strong reputation for providing high quality science, expertise and services in drug metabolism and GLP bioanalysis for over 25 years made XBL an attractive partner for SOLVO.”, noted Ernõ Duda, President and CEO of SOLVO, “Being able to offer transporter assays within XBL’s facilities in New Jersey in the United States fits well with our business strategy of increasing our presence in the US, broadening our portfolio with GLP studies and partnering with companies who’s portfolio complements ours, and vice versa”.
The addition of transporter services is reflective of XBL continuous effort to enhance its core services in the bioanalytical, non-clinical ADME, and metabolite profiling areas to provide the best CRO services to the pharmaceutical, biotechnology, animal health and agrochemical industries. XBL facilities in Plainsboro, NJ (www.xbl.com) and Nanjing, China (www.xbl-china.com) operate to GLP standards, are licensed for the use of radioisotopes, and are AAALAC accredited for animal research.
For further information, contact:
Dennis P. Heller, Ph.D., VP Pharmaceutical Development, email@example.com or inquire at www.xbl.com
|©2005-2017, XenoBiotic Laboratories, Inc. All rights reserved.
Website created by Princeton Internet Group (PING)